BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 9888475)

  • 1. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer.
    Vermeulen PB; Van den Eynden GG; Huget P; Goovaerts G; Weyler J; Lardon F; Van Marck E; Hubens G; Dirix LY
    Br J Cancer; 1999 Jan; 79(2):316-22. PubMed ID: 9888475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microvessel density, cyclo-oxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancer.
    Liang JT; Huang KC; Jeng YM; Lee PH; Lai HS; Hsu HC
    Br J Surg; 2004 Mar; 91(3):355-61. PubMed ID: 14991639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of the c-erb B-2, nm23, bcl-2 and p53 protein markers on colorectal cancer.
    Demirbaş S; Sücüllü I; Yildirim S; Celenk T
    Turk J Gastroenterol; 2006 Mar; 17(1):13-9. PubMed ID: 16830272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival.
    Edler D; Kressner U; Ragnhammar P; Johnston PG; Magnusson I; Glimelius B; Påhlman L; Lindmark G; Blomgren H
    Clin Cancer Res; 2000 Feb; 6(2):488-92. PubMed ID: 10690528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse.
    Giatromanolaki A; Sivridis E; Stathopoulos GP; Fountzilas G; Kalofonos HP; Tsamandas A; Vrettou E; Scopa C; Polychronidis A; Simopoulos K; Koukourakis MI
    Anticancer Res; 2001; 21(1A):253-9. PubMed ID: 11299743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up.
    Theodoropoulos GE; Karafoka E; Papailiou JG; Stamopoulos P; Zambirinis CP; Bramis K; Panoussopoulos SG; Leandros E; Bramis J
    Anticancer Res; 2009 Feb; 29(2):785-91. PubMed ID: 19331236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation of microvessel density with microvascular invasion, metastasis and prognosis in renal cell carcinoma.
    Yildiz E; Ayan S; Goze F; Gokce G; Gultekin EY
    BJU Int; 2008 Mar; 101(6):758-64. PubMed ID: 18070177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Multivariate regression analysis of recurrence following curative surgery for colorectal cancer].
    Liang JL; Wan DS; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Wu XJ
    Ai Zheng; 2004 May; 23(5):564-7. PubMed ID: 15142455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 alterations are associated with improved prognosis in distal colonic carcinomas.
    Soong R; Grieu F; Robbins P; Dix B; Chen D; Parsons R; House A; Iacopetta B
    Clin Cancer Res; 1997 Aug; 3(8):1405-11. PubMed ID: 9815825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer.
    Edler D; Hallström M; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
    Clin Cancer Res; 2000 Apr; 6(4):1378-84. PubMed ID: 10778966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas.
    Li M; Li JY; Zhao AL; Gu J
    Oncology; 2007; 73(1-2):52-7. PubMed ID: 18334831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer.
    Kressner U; Lindmark G; Gerdin B; Påhlman L; Glimelius B
    Anticancer Res; 1996; 16(2):951-7. PubMed ID: 8687158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of tumor localization on the prognostic value of P53 protein in colorectal adenocarcinomas.
    Diez M; Medrano M; Mugüerza JM; Ramos P; Hernandez P; Villeta R; Martín A; Noguerales F; Ruiz A; Granell J
    Anticancer Res; 2000; 20(5C):3907-12. PubMed ID: 11268475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers.
    Jernvall P; Mäkinen MJ; Karttunen TJ; Mäkelä J; Vihko P
    Br J Cancer; 1999 Feb; 79(5-6):903-8. PubMed ID: 10070888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VEGF and bFGF expression and microvessel density of maxillary sinus squamous cell carcinoma in relation to p53 status, spontaneous apoptosis and prognosis.
    Bandoh N; Hayashi T; Takahara M; Kishibe K; Ogino T; Katayama A; Imada M; Nonaka S; Harabuchi Y
    Cancer Lett; 2004 May; 208(2):215-25. PubMed ID: 15142681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of a new classification system for curatively resected colorectal adenocarcinoma.
    Sternberg A; Sibirsky O; Cohen D; Blumenson LE; Petrelli NJ
    Cancer; 1999 Sep; 86(5):782-92. PubMed ID: 10463976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
    Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
    BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of molecular marker expression can predict clinical outcome in colon carcinomas.
    Galizia G; Lieto E; Ferraraccio F; Orditura M; De Vita F; Castellano P; Imperatore V; Romano C; Ciardiello F; Agostini B; Pignatelli C
    Clin Cancer Res; 2004 May; 10(10):3490-9. PubMed ID: 15161706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.
    Garrity MM; Burgart LJ; Mahoney MR; Windschitl HE; Salim M; Wiesenfeld M; Krook JE; Michalak JC; Goldberg RM; O'Connell MJ; Furth AF; Sargent DJ; Murphy LM; Hill E; Riehle DL; Meyers CH; Witzig TE;
    J Clin Oncol; 2004 May; 22(9):1572-82. PubMed ID: 15117979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.